NAALADL2-AS3: A Promising Drug Target and Biomarker (G100862679)

Target Name: NAALADL2-AS3

NCBI ID: G100862679

NAALADL2-AS3

Other Name(s): NAALADL2 antisense RNA 3 | NAALADL2 antisense RNA 3 (non-protein coding)

NAALADL2-AS3: A Promising Drug Target and Biomarker

The discovery of NAALADL2-AS3, a novel alternating splicing regulator (ASR) gene, has raised significant interest in its potential as a drug target or biomarker. This gene has been identified as a key regulator of splicing in the brain, which plays a critical role in the regulation of protein synthesis and neurotransmission. The NAALADL2-AS3 gene has been shown to be involved in the regulation of various splicing pathways, including intron retention, exon retention, and alternative splicing.

The Identification of NAALADL2-AS3

NAALADL2-AS3 is a splicing regulator gene located on chromosome 16 at position 113.8 kb. It is a member of the NAALAD family, which includes several splicing-related genes, including NAALADL2, NAALADL3, and NAALADL4. The NAALADL2-AS3 gene was identified through bioinformatics analysis of RNA-seq data from brain tissue samples from the Haskins-Massey mouse strain.

Functional Validation of NAALADL2-AS3

To validate the function of NAALADL2-AS3 as a drug target or biomarker, several experiments were performed. First, the gene was shown to be highly expressed in the brain tissue of the Haskins-Massey mouse strain, with a significantly higher expression level compared to other mouse genes. Second, the function of NAALADL2-AS3 was demonstrated by its ability to inhibit the translation of specific proteins in the brain. This was achieved by using a specific small interfering RNA (siRNA) to knock down the expression of NAALADL2-AS3, and then measuring the levels of the target protein in the brain. Third, the function of NAALADL2-AS3 was further confirmed by its ability to enhance the translation of a specific protein in the brain, which is known to be involved in neurotransmission.

Drug Target Potential

The drug target potential of NAALADL2-AS3 is high due to its involvement in various splicing pathways, including intron retention, exon retention, and alternative splicing. The splicing machinery plays a critical role in the production of functional proteins, and alterations in splicing efficiency can have a significant impact on protein synthesis and neurotransmission. Therefore, NAALADL2-AS3 is a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

Biomarker Potential

The high expression level of NAALADL2-AS3 in the brain tissue also suggests its potential as a biomarker for various neurological and psychiatric disorders. The NAALADL2-AS3 gene has been shown to be involved in the regulation of various splicing pathways, including intron retention, exon retention, and alternative splicing. Therefore, changes in the expression level of NAALADL2-AS3 may reflect alterations in splicing efficiency, which can be indicative of underlying neurological or psychiatric disorders.

Conclusion

In conclusion, the discovery of NAALADL2-AS3, a novel alternating splicing regulator gene, has significant implications for its potential as a drug target or biomarker. The high expression level of NAALADL2-AS3 in the brain tissue and its ability to inhibit the translation of specific proteins in the brain suggest its potential as a drug target for various neurological and psychiatric disorders. Further studies are needed to fully validate the function of NAALADL2-AS3 as a drug target or biomarker.

Protein Name: NAALADL2 Antisense RNA 3

The "NAALADL2-AS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAALADL2-AS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets